Skip to main content
Log in

New trials support use of abciximab in PTCA

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

The risk of life-threatening complications associated with angioplasty are significantly reduced by a single dose of Centocor’s glycoprotein IIb/IIIa receptor antagonist abciximab [c7E3], compared with placebo, according to the results of the EPILOG * and CAPTURE * trials, and the latest results from the EPIC * study. The EPILOG and CAPTURE trials were terminated early due to the obvious treatment-associated clinical benefits that were seen during interim analyses. Data from the analyses were presented at the 18th Congress of the European Society of Cardiology (ESC) [ Birmingham, UK; August 1996 ]. In another study presented at the conference, referred to as ISAR * , researchers showed that adjunctive antiplatelet therapy provided greater clinical benefit than anticoagulant therapy in patients undergoing intracoronary stent placement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jack, D.B. New trials support use of abciximab in PTCA. Inpharma Wkly. 1053, 3–4 (1996). https://doi.org/10.2165/00128413-199610530-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199610530-00003

Keywords

Navigation